A Breakthrough in Chronic Disease Management

Kilele Health’s SunVida™ System Unlocks the Biochemical Data Layer for Precision Medicine

Precision medicine has made progress—but it’s still missing something essential.

AI, analytics, and digital health tools are advancing rapidly. Yet truly personalized care remains out of reach because biochemical data beyond glucose is largely invisible outside the clinic. Without continuous molecular insight, remote care is limited, population health data is incomplete, and care too often remains reactive, expensive, and one-size-fits-all.

That’s where Kilele Health comes in.

Real-Time Biochemistry, Finally Within Reach

SunVida unlocks the biochemical data layer—delivering real-time and longitudinal molecular information that has never before been accessible at scale. SunVida transforms complex biology into actionable insights for both individuals and populations, enabling:

• More personalized treatment decisions

• Earlier intervention outside the hospital

• Smarter transitions from clinic to home

• Better outcomes at lower cost

Powering the Next Era of Personalized Healthcare

With SunVida, clinicians and patients can move beyond snapshots and retrospective data to continuous, data-driven, and predictive care—guided by what’s actually happening in the body, in real time as well as based on proprietary analysis of longitudinal data.

By making biochemical data accessible, interpretable, and actionable, Kilele Health is redefining what precision medicine can be. The next era of personalized healthcare is here—and it’s being built on SunVida.

Real-Time Decision Support—Empowering Patients, Enabling Smarter Care

The First Wave of the New Era of Precision Medicine

  • Phenylketonuria

    Phenylketonuria (PKU) is a rare genetic condition affecting both children and adults. Without careful management, phenylalanine (Phe) accumulates in the blood, leading to serious complications such as irreversible cognitive impairment, emotional instability, and neurologic decline.

    Managing PKU requires constant vigilance. Patients—especially children and their families—must follow a highly restrictive diet, often combined with supplements, formula, and medications, to keep blood Phe levels within a narrow therapeutic range. Today, this management relies on infrequent blood tests and delayed feedback, making day-to-day control difficult and stressful.

    Kilele Health aims to change this paradigm.

    By providing real-time phenylalanine insights, the SunVida™ platform has the potential to give PKU patients and care teams continuous visibility into metabolic control—enabling faster adjustments to diet, supplements, formula, and therapy. Much like continuous glucose monitoring transformed life for people with type 1 diabetes, real-time Phe monitoring can empower PKU patients to move from reactive management to proactive control, improving adherence, reducing variability, and supporting healthier long-term outcomes.

  • GLP-1's

    GLP-1 therapies have transformed weight management and delivered meaningful cardiometabolic benefits for millions of people. However, rapid weight loss inevitably places stress on muscle tissue, and in some patients this can progress to clinically significant muscle loss (sarcopenia).

    When muscle weakness or fatigue becomes pronounced, patients may be forced to pause or discontinue GLP-1 therapy before reaching their target weight, forfeiting the full health benefits of treatment.

    Kilele Health aims to change this outcome.

    By providing real-time insight into protein metabolism with phenylalanine trends (along with additional biomarkers over time) SunVida™ intends to enable improved management of nutrition and physical activity. This should support GLP-1 continuation to target weight without unacceptable muscle weakness, enabling patients to achieve healthier, more sustainable outcomes.

The Second Wave of the New Era of Precision Medicine

SunVida™ Platform

The SunVida™ platform is enabled by next-generation aptamer sensor technology.  The advantage of aptamers is clear: no-other platform approach has been demonstrated as broadly in-vivo.  Aptamers also excel in-vitro and can now quantify nearly half the human proteome in a single commercial assay.

These advantages for aptamers represent their historical strengths but fail to address their major weakness in sensor longevity.  Kilele Health is the first to solve and first to patent against the aptamer longevity problem by matching the 2-week factory-calibrated performance now ubiquitous with glucose monitors.  

Kilele Health's technical strength is making the highest accuracy sensors on proven glucose monitor-style device formats and preserving that accuracy for weeks or more.  Kilele Health then deploys this technical strength against the most compelling needs in chronic disease management.

Kilele Health in the News

All News

Experienced Startup Team

Over 50 years of medtech and startup experience, including multiple exits and M&A deals.

Meet the Team

Contact Us

Are you interested in collaborating with us? We invite you to share your information, and we’ll reach out to you soon. Together, we can bring great ideas to life. We can’t wait to connect and explore the amazing possibilities ahead!